Participate in MDMA Studies
We are currently recruiting for the Phase 3 study of MDMA-assisted therapy for PTSD. Here is a list of all MAPS-sponsored trials on clinicaltrials.gov.
Read our Publications
MAPS PBC publishes research papers detailing the results of our clinical trials.
MAPS PBC in the Media
The Psychedelic Revolution Is Coming. Psychiatry May Never Be the Same.
May 09, 2021
A Psychedelic Drug Passes Big Test for PTSD Treatment
May 03, 2021
New PTSD Treatments Emerge as Cases Rise Among Some Groups
Sept. 21, 2020
PTSD and psychoactive drugs: MDMA treatment shows potential, but others lack evidence
Sept. 21, 2020
The case for funding psychedelics to treat mental health
Oct 9, 2020
Announcements
Publication of MAPP1 Results in Nature Medicine: A Message from Amy Emerson, MAPS PBC CEO
We’ve finally reached the point where we can shout our good news from the roof tops and publicly celebrate the work of this amazing team! The publication of our MAPP1 findings is official as of this morning, May 10th, in Nature Medicine! Nature Medicine is one of the...
MDMA-Assisted Group Therapy for PTSD Among Veterans Study Will Proceed Following Successful Safety Negotiations
The FDA lifted the clinical hold from a MAPS-sponsored Phase 2 study of MDMA-assisted group therapy for the treatment of posttraumatic stress disorder among veterans at the VA Portland Health Care System This essential proof-of-principle study tests safety and...
Novel PTSD Treatment Advances Toward Regulatory Evaluation with New Collaboration
On PTSD Awareness Day, MAPS PBC announces plans to develop the New Drug Application for MDMA-assisted therapy in collaboration with MMS Holdings The second Phase 3 trial of the Breakthrough-Designated Therapy for PTSD will be completed in late 2022, with a targeted...
MAPS Appoints Jeff George and Dan Grossman to MAPS PBC Board of Directors
Experienced healthcare leaders bring decades of experience in global drug commercialization and patient access Appointment brings significant pharmaceutical leadership experience to the MAPS PBC board MDMA-assisted therapy, a novel treatment for PTSD with FDA...
MAPS PBC is a wholly-owned subsidiary of the Multidisciplinary Association for Psychedelic Studies (MAPS). MAPS is a 501(c)(3) non-profit research and educational organization that develops medical, legal, and cultural contexts for people to benefit from the careful uses of psychedelics and marijuana.